As of 2026-03-24, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -5.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 2,691.69 mil USD. RARE's TTM EBITDA according to its financial statements is -499.79 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 13.9x | 13.8x |
| Forward P/E multiples | 17.6x - 21.4x | 19.8x |
| Fair Price | (98.51) - (79.27) | (94.48) |
| Upside | -586.0% - -491.1% | -566.1% |
| Date | EV/EBITDA |
| 2026-03-23 | -5.39 |
| 2026-03-20 | -5.31 |
| 2026-03-19 | -5.41 |
| 2026-03-18 | -5.42 |
| 2026-03-17 | -5.64 |
| 2026-03-16 | -5.69 |
| 2026-03-13 | -5.59 |
| 2026-03-12 | -5.66 |
| 2026-03-11 | -5.76 |
| 2026-03-10 | -5.88 |
| 2026-03-09 | -5.84 |
| 2026-03-06 | -5.58 |
| 2026-03-05 | -5.62 |
| 2026-03-04 | -5.68 |
| 2026-03-03 | -5.73 |
| 2026-03-02 | -5.92 |
| 2026-02-27 | -5.99 |
| 2026-02-26 | -5.92 |
| 2026-02-25 | -5.90 |
| 2026-02-24 | -5.87 |
| 2026-02-23 | -5.82 |
| 2026-02-20 | -5.86 |
| 2026-02-19 | -5.69 |
| 2026-02-18 | -5.42 |
| 2026-02-17 | -5.37 |
| 2026-02-13 | -5.43 |
| 2026-02-12 | -6.01 |
| 2026-02-11 | -6.08 |
| 2026-02-10 | -6.15 |
| 2026-02-09 | -6.08 |
| 2026-02-06 | -6.24 |
| 2026-02-05 | -6.07 |
| 2026-02-04 | -6.24 |
| 2026-02-03 | -6.26 |
| 2026-02-02 | -6.25 |
| 2026-01-30 | -6.12 |
| 2026-01-29 | -6.16 |
| 2026-01-28 | -6.19 |
| 2026-01-27 | -6.23 |
| 2026-01-26 | -6.17 |
| 2026-01-23 | -6.15 |
| 2026-01-22 | -5.99 |
| 2026-01-21 | -5.87 |
| 2026-01-20 | -5.84 |
| 2026-01-16 | -5.81 |
| 2026-01-15 | -6.01 |
| 2026-01-14 | -6.12 |
| 2026-01-13 | -6.13 |
| 2026-01-12 | -6.18 |
| 2026-01-09 | -5.82 |